Experimental PSP drug shows promise in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged ≥41 years to ≤ 85 years. * Clinical diagnosis of probable progressive supranuclear palsy (PSP). * Patient is on a stable therapy for a neurological drug for at least 1 month prior to screening visit. * Patients who are able to walk 3 meters or more independently or with assistive devices. * Score 15 points ≥ on the Korean Mini-Mental Status Exam (K-MMSE) at the screening visit. * Have reliable caregiver to accompany participant to all study visits. * Patients and/or their representatives who have voluntarily provided a written consent for participation in this clinical study. Exclusion Criteria: * Patients who have Presence of structural lesions or Suspected concurrent onset of central nervous system diseases based on the CT/MRI scan results and neurological examinations performed within 12 months of screening or at screening. * Patients with a history of known or suspected seizures. * Patients with a recent unexplained loss of consciousness within 3 months prior to screening or a history of significant head trauma with loss of consciousness. * Patients with acute or unstable cardiovascular disease, uncontrolled hypertension, uncontrolled diabetes, or any other medical condition that can interfere with completing the clinical study. * Patients with hypersensitivity reactions to the ingredients of the investigational product. * Patients with a history of cancer within 5 years prior to screening. * Patients with abnormal renal function. * Patients with severe liver function abnormalities. * Patients weighing ≤35 kg. * Among the female subjects who does not agree to use proper contraception. * Pregnant or breastfeeding women. * Patients who participated in another clinical study within 4 weeks prior to screening and were administered investigational products or were applied investigational medical devices. * Patients who were administered the study drug (GV1001) of this clinical study within 12 months prior to screening. * Patients who participated in a clinical study for progressive supranuclear palsy within 6 months prior to screening. * Other patients judged by the investigator as ineligible to participate in this clinical study.